SCA
CADX

SAC Capital Advisors’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

SAC Capital Advisors’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-17,842
Closed -$161K – 2189
2013
Q4 		$161K Buy
17,842
+11,742
+192% +$84.8K ﹤0.01% 1674
2013
Q3 		$38K Sell
6,100
-10,377
-63% -$66K ﹤0.01% 1729
2013
Q2 		$112K Buy
+16,477
New +$115K ﹤0.01% 1534

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAC Capital Advisors's CADX Position: Q1 2014 in Review

SAC Capital Advisors sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 17,842 shares — an estimated $161K sold.

SAC Capital Advisors first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $161K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • SAC Capital Advisors reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 17,842 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $161K.
  • SAC Capital Advisors first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • SAC Capital Advisors's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $161K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on SAC Capital Advisors's 13F filing for Q1 2014, filed 15 May 2014.